|
1
|
Lenz A, Franklin GA and Cheadle WG:
Systemic inflammation after trauma. Injury. 38:1336–1345. 2007.
|
|
2
|
Esposito E and Cuzzocrea S: TNF-alpha as a
therapeutic target in inflammatory diseases, ischemia-reperfusion
injury and trauma. Curr Med Chem. 16:3152–3167. 2009.
|
|
3
|
Woodcock T and Morganti-Kossmann MC: The
role of markers of inflammation in traumatic brain injury. Front
Neurol. 4:182013.
|
|
4
|
Vandenabeele P, Declercq W, Beyaert R and
Fiers W: Two tumour necrosis factor receptors: structure and
function. Trends Cell Biol. 5:392–399. 1995.
|
|
5
|
Loetscher H, Pan YC, Lahm HW, Gentz R,
Brockhaus M, Tabuchi H and Lesslauer W: Molecular cloning and
expression of the human 55 kd tumor necrosis factor receptor. Cell.
61:351–359. 1990.
|
|
6
|
Smith CA, Davis T, Anderson D, et al: A
receptor for tumor necrosis factor defines an unusual family of
cellular and viral proteins. Science. 248:1019–1023. 1990.
|
|
7
|
Goodwin RG, Anderson D, Jerzy R, et al:
Molecular cloning and expression of the type 1 and type 2 murine
receptors for tumor necrosis factor. Mol Cell Biol. 11:3020–3026.
1991.
|
|
8
|
Tartaglia LA, Weber RF, Figari IS,
Reynolds C, Palladino MA Jr and Goeddel DV: The two different
receptors for tumor necrosis factor mediate distinct cellular
responses. Proc Natl Acad Sci USA. 88:9292–9296. 1991.
|
|
9
|
Choi SJ, Lee KH, Park HS, Kim SK, Koh CM
and Park JY: Differential expression, shedding, cytokine regulation
and function of TNFR1 and TNFR2 in human fetal astrocytes. Yonsei
Med J. 46:818–826. 2005.
|
|
10
|
Cinat M, Waxman K, Vaziri ND, Daughters K,
Yousefi S, Scannell G and Tominaga GT: Soluble cytokine receptors
and receptor antagonists are sequentially released after trauma. J
Trauma. 39:112–120. 1995.
|
|
11
|
Ertel W, Keel M, Bonaccio M, Steckholzer
U, Gallati H, Kenney JS and Trentz O: Release of anti-inflammatory
mediators after mechanical trauma correlates with severity of
injury and clinical outcome. J Trauma. 39:879–887. 1995.
|
|
12
|
Stein DM, Lindell A, Murdock KR, et al:
Relationship of serum and cerebrospinal fluid biomarkers with
intracranial hypertension and cerebral hypoperfusion after severe
traumatic brain injury. J Trauma. 70:1096–1103. 2011.
|
|
13
|
Dalgard CL, Cole JT, Kean WS, et al: The
cytokine temporal profile in rat cortex after controlled cortical
impact. Front Mol Neurosci. 5:62012.
|
|
14
|
Hoch RC, Rodriguez R, Manning T, Bishop M,
Mead P, Shoemaker WC and Abraham E: Effects of accidental trauma on
cytokine and endotoxin production. Crit Care Med. 21:839–845.
1993.
|
|
15
|
Rabinovici R, John R, Esser KM, Vernick J
and Feuerstein G: Serum tumor necrosis factor-alpha profile in
trauma patients. J Trauma. 35:698–702. 1993.
|
|
16
|
Tan LR, Waxman K, Scannell G, Ioli G and
Granger GA: Trauma causes early release of soluble receptors for
tumor necrosis factor. J Trauma. 34:634–638. 1993.
|
|
17
|
Cinat ME, Waxman K, Granger GA, Pearce W,
Annas C and Daughters K: Trauma causes sustained elevation of
soluble tumor necrosis factor receptors. J Am Coll Surg.
179:529–537. 1994.
|
|
18
|
Svoboda P, Kantorová I and Ochmann J:
Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha
in multiple trauma patients. J Trauma. 36:336–340. 1994.
|
|
19
|
Majetschak M, Flach R, Heukamp T, et al:
Regulation of whole blood tumor necrosis factor production upon
endotoxin stimulation after severe blunt trauma. J Trauma.
43:880–887. 1997.
|
|
20
|
Spielmann S, Kerner T, Ahlers O, Keh D,
Gerlach M and Gerlach H: Early detection of increased tumour
necrosis factor alpha (TNFalpha) and soluble TNF receptor protein
plasma levels after trauma reveals associations with the clinical
course. Acta Anaesthesiol Scand. 45:364–370. 2001.
|
|
21
|
Zerey M, Burns JM, Kercher KW, Kuwada TS
and Heniford BT: Minimally invasive management of colon cancer.
Surg Innov. 13:5–15. 2006.
|
|
22
|
Feldman AM: TNF alpha - still a
therapeutic target. Clin Transl Sci. 1:1452008.
|
|
23
|
Kawasaki Y, Zhang L, Cheng JK and Ji RR:
Cytokine mechanisms of central sensitization: distinct and
overlapping role of interleukin-1beta, interleukin-6, and tumor
necrosis factor-alpha in regulating synaptic and neuronal activity
in the superficial spinal cord. J Neurosci. 28:5189–5194. 2008.
|
|
24
|
Oshima T, Lee S, Sato A, Oda S, Hirasawa H
and Yamashita T: TNF-alpha contributes to axonal sprouting and
functional recovery following traumatic brain injury. Brain Res.
1290:102–110. 2009.
|
|
25
|
Spinas GA, Keller U and Brockhaus M:
Release of soluble receptors for tumor necrosis factor (TNF) in
relation to circulating TNF during experimental endotoxinemia. J
Clin Invest. 90:533–536. 1992.
|
|
26
|
Van Zee KJ, Kohno T, Fischer E, Rock CS,
Moldawer LL and Lowry SF: Tumor necrosis factor soluble receptors
circulate during experimental and clinical inflammation and can
protect against excessive tumor necrosis factor alpha in vitro and
in vivo. Proc Natl Acad Sci USA. 89:4845–4849. 1992.
|
|
27
|
Gerlach H, Gerlach M and Clauss M:
Relevance of tumour necrosis factor-alpha and interleukin-1-alpha
in the pathogenesis of hypoxia-related organ failure. Eur J
Anaesthesiol. 10:273–285. 1993.
|
|
28
|
Rogy MA, Coyle SM, Oldenburg HS, et al:
Persistently elevated soluble tumor necrosis factor receptor and
interleukin-1 receptor antagonist levels in critically ill
patients. J Am Coll Surg. 178:132–138. 1994.
|
|
29
|
Pellegrini JD, Puyana JC, Lapchak PH,
Kodys K and Miller-Graziano CL: A membrane TNF-alpha/TNFR ratio
correlates to MODS score and mortality. Shock. 6:389–396. 1996.
|
|
30
|
Froon AH, Bemelmans MH, Greve JW, van der
Linden CJ and Buurman WA: Increased plasma concentrations of
soluble tumor necrosis factor receptors in sepsis syndrome:
correlation with plasma creatinine values. Crit Care Med.
22:803–809. 1994.
|
|
31
|
Balk RA: Pathogenesis and management of
multiple organ dysfunction or failure in severe sepsis and septic
shock. Crit Care Clin. 16:337–352. 2000.
|
|
32
|
Esposito E and Cuzzocrea S: Anti-TNF
therapy in the injured spinal cord. Trends Pharmacol Sci.
32:107–115. 2011.
|
|
33
|
Chio CC, Chang CH, Wang CC, et al:
Etanercept attenuates traumatic brain injury in rats by reducing
early microglial expression of tumor necrosis factor-α. BMC
Neurosci. 14:332013.
|
|
34
|
Shuh M, Bohorquez H, Loss GE Jr and Cohen
AJ: Tumor necrosis factor-α: life and death of hepatocytes during
liver ischemia/reperfusion injury. Ochsner J. 13:119–130. 2013.
|
|
35
|
Tobinick E, Kim NM, Reyzin G,
Rodriguez-Romanacce H and DePuy V: Selective TNF inhibition for
chronic stroke and traumatic brain injury: an observational study
involving 629 consecutive patients treated with perispinal
etanercept. CNS Drugs. 26:1051–1070. 2012.
|
